# Comprehensive tumour‐immune profiling reveals TREM2+ tumour‐associated macrophages facilitating lymph node metastasis in head and neck squamous cell carcinoma

**Authors:** Zhuokai Wu, Chixing Cheng, Zhaoxin Li, Minyi Ren, Hongxi Cao, Weijie Huang, Jun Wang, Lixian Wu, Tingyi Lee, Sien Zhang, Hanhao Zheng, Yixi Wang

PMC · DOI: 10.1002/ctm2.70604 · 2026-01-30

## TL;DR

This study identifies TREM2+ tumor-associated macrophages as key drivers of lymph node metastasis in head and neck cancer by suppressing immune cells.

## Contribution

The study reveals a novel mechanism by which TREM2+ TAMs promote metastasis via the SPP1–CD44–BHLHE40 axis and CD8+ T cell exhaustion.

## Key findings

- TREM2+ TAMs promote CD8+ T cell exhaustion through the SPP1–CD44–BHLHE40 axis in HNSCC.
- CD8+ T cell exhaustion induced by TREM2+ TAMs facilitates tumor immune escape and lymph node metastasis.

## Abstract

Lymph node (LN) metastasis is a well‐established independent prognostic factor in head and neck squamous cell carcinoma (HNSCC). Formation of suppressive tumour immune microenvironment (TIME) is a major contributor to tumour immune evasion and metastasis. However, the TIME landscape underlying LN‐metastatic HNSCC remains poorly elucidated.

A total of 688 866 single‐cell transcriptomes across 212 HNSCC samples were integrated. Comprehensive bioinformatic analyses on single‐cell RNA sequencing and microarray datasets revealed a TREM2+ tumour‐associated macrophage (TAM) cluster associated with LN metastasis. The functional role of TREM2+ TAMs was investigated through multiplex immunohistochemistry (mIHC) staining in clinical HNSCC cohort and in vitro co‐culture experiments. Furthermore, machine learning algorithms were employed to construct a prognostic model for HNSCC.

Integrative single‐cell analysis revealed the immunosuppressive TIME of LN‐metastatic HNSCC, characterised by high infiltration of exhausted CD8+ T cells (CD8+ Tex). We identified a specific TREM2+ TAM cluster that was strongly associated with CD8+ Tex infiltration and LN metastasis. In vitro experiment confirmed that TREM2+ TAMs promoted CD8+ T cell exhaustion. Mechanistically, TREM2+ TAMs exhibited a terminally differentiated phenotype driven by ETV5, and secreted SPP1 to interact with CD44 on CD8+ T cells, thus upregulating BHLHE40 to promote CD8+ Tex formation. Clinically, a prognostic model based on TREM2+ TAM signature genes was trained to independently predict HNSCC outcomes.

This study delineates the mechanism that TREM2+ TAMs promote LN metastasis in HNSCC by facilitating CD8+ T cells exhaustion via SPP1–CD44–BHLHE40 axis, proposing TREM2+ TAMs as potential therapeutic target for HNSCC.

(1) TREM2+ TAMs promote CD8+ T cell exhaustion by upregulating BHLHE40 through the SPP1–CD44 axis, contributing to a suppressive tumour immune microenvironment in HNSCC. (2) CD8+ Tex induced by TREM2+ TAMs facilitates immune escape and promotes tumour cell metastasis via the lymphangion.

## Linked entities

- **Genes:** TREM2 (triggering receptor expressed on myeloid cells 2) [NCBI Gene 54209], SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696], CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960], BHLHE40 (basic helix-loop-helix family member e40) [NCBI Gene 8553], ETV5 (ETS variant transcription factor 5) [NCBI Gene 2119]
- **Diseases:** head and neck squamous cell carcinoma (MONDO:0010150), HNSCC (MONDO:0010150)

## Full-text entities

- **Genes:** S100A14 (S100 calcium binding protein A14) [NCBI Gene 57402] {aka BCMP84, S100A15}, RPL22 (ribosomal protein L22) [NCBI Gene 6146] {aka EAP, HBP15, HBP15/L22, L22, eL22}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, TXNIP (thioredoxin interacting protein) [NCBI Gene 10628] {aka ARRDC6, EST01027, HHCPA78, THIF, VDUP1}, CLEC4C (C-type lectin domain family 4 member C) [NCBI Gene 170482] {aka BDCA-2, BDCA2, CD303, CLECSF11, CLECSF7, DLEC}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, TAM (Myeloproliferative syndrome, transient (transient abnormal) [NCBI Gene 8205] {aka MST}, TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}, ETV5 (ETS variant transcription factor 5) [NCBI Gene 2119] {aka ERM}, CLEC3B (C-type lectin domain family 3 member B) [NCBI Gene 7123] {aka MCDR4, TN, TNA}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}, VCAN (versican) [NCBI Gene 1462] {aka CSPG2, ERVR, GHAP, PG-M, WGN, WGN1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, FCN1 (ficolin 1) [NCBI Gene 2219] {aka FCNM}, TOX (thymocyte selection associated high mobility group box) [NCBI Gene 9760] {aka TOX1}, CFD (complement factor D) [NCBI Gene 1675] {aka ADIPSIN, ADN, DF, PFD}, THBS1 (thrombospondin 1) [NCBI Gene 7057] {aka THBS, THBS-1, TSP, TSP-1, TSP1}, NFYB (nuclear transcription factor Y subunit beta) [NCBI Gene 4801] {aka CBF-A, CBF-B, HAP3, NF-YB}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, TREM2 (triggering receptor expressed on myeloid cells 2) [NCBI Gene 54209] {aka AD17, PLOSL2, TREM-2, Trem2a, Trem2b, Trem2c}, S100A11 (S100 calcium binding protein A11) [NCBI Gene 6282] {aka HEL-S-43, MLN70, S100C}, TPSAB1 (tryptase alpha/beta 1) [NCBI Gene 7177] {aka TPS1, TPS2, TPSB1, TPSB2, Tryptase-2}, MS4A1 (membrane spanning 4-domains A1) [NCBI Gene 931] {aka B1, Bp35, CD20, CVID5, FMC7, LEU-16}, CD2 (CD2 molecule) [NCBI Gene 914] {aka LFA-2, SRBC, T11}, GZMK (granzyme K) [NCBI Gene 3003] {aka GrK, TRYP2}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, TPSB2 (tryptase beta 2) [NCBI Gene 64499] {aka TPS2, tryptaseB, tryptaseC}, LEF1 (lymphoid enhancer binding factor 1) [NCBI Gene 51176] {aka ECTD1, ECTD17, LEF-1, TCF10, TCF1ALPHA, TCF7L3}, CD82 (CD82 molecule) [NCBI Gene 3732] {aka 4F9, C33, GR15, IA4, KAI1, R2}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, GFI1 (growth factor independent 1 transcriptional repressor) [NCBI Gene 2672] {aka GFI-1, GFI1A, SCN2, ZNF163}, FCGR3B (Fc gamma receptor IIIb) [NCBI Gene 2215] {aka CD16, CD16-I, CD16b, FCG3, FCGR3, FCRIIIb}, BIRC3 (baculoviral IAP repeat containing 3) [NCBI Gene 330] {aka AIP1, API2, CIAP2, HAIP1, HIAP1, IAP-1}, STK17A (serine/threonine kinase 17a) [NCBI Gene 9263] {aka DRAK1}, CST12P (cystatin 12, pseudogene) [NCBI Gene 106478911] {aka Cst, Ctes4, E2}, MNDA (myeloid cell nuclear differentiation antigen) [NCBI Gene 4332] {aka PYHIN3}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, IL7R (interleukin 7 receptor) [NCBI Gene 3575] {aka CD127, CDW127, IL-7R-alpha, IL-7Ralpha, IL7RA, IL7Ralpha}, DCN (decorin) [NCBI Gene 1634] {aka CSCD, DSPG2, PG40, PGII, PGS2, SLRR1B}, IGKC (immunoglobulin kappa constant) [NCBI Gene 3514] {aka HCAK1, IGKCD, Km}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, USF2 (upstream transcription factor 2, c-fos interacting) [NCBI Gene 7392] {aka FIP, bHLHb12}, HCAR3 (hydroxycarboxylic acid receptor 3) [NCBI Gene 8843] {aka GPR109B, HCA3, HM74, PUMAG, Puma-g}, SERPINH1 (serpin family H member 1) [NCBI Gene 871] {aka AsTP3, CBP1, CBP2, HSP47, OI10, PIG14}, CD6 (CD6 molecule) [NCBI Gene 923] {aka TP120}, ISG15 (ISG15 ubiquitin like modifier) [NCBI Gene 9636] {aka G1P2, IFI15, IMD38, IP17, UCRP, hUCRP}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, EXOSC4 (exosome component 4) [NCBI Gene 54512] {aka RRP41, RRP41A, Rrp41p, SKI6, Ski6p, hRrp41p}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, GNLY (granulysin) [NCBI Gene 10578] {aka D2S69E, LAG-2, LAG2, NKG5, TLA519}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, ENO1 (enolase 1) [NCBI Gene 2023] {aka ENO1-IT1, ENO1L1, HEL-S-17, MPB1, NNE, PPH}, IFT25 (intraflagellar transport 25) [NCBI Gene 51668] {aka C1orf41, CFAP232, FAP232, HSPB11, HSPCO34, PP25}, BATF (basic leucine zipper ATF-like transcription factor) [NCBI Gene 10538] {aka B-ATF, BATF1, SFA-2, SFA2}, HAVCR2 (hepatitis A virus cellular receptor 2) [NCBI Gene 84868] {aka CD366, HAVcr-2, KIM-3, SPTCL, TIM3, TIMD-3}, LILRA4 (leukocyte immunoglobulin like receptor A4) [NCBI Gene 23547] {aka CD85g, ILT7}, TNFAIP6 (TNF alpha induced protein 6) [NCBI Gene 7130] {aka TSG-6, TSG6}
- **Diseases:** metastases (MESH:D009362), leukoplakia (MESH:D007971), T (MESH:D001260), node (MESH:D012804), deaths (MESH:D003643), LN (MESH:D000072717), necrotic (MESH:D009336), metastatic (MESH:D000092182), LN metastasis (MESH:D008207), HNSCC (MESH:D000077195), TAMs (MESH:D009369)
- **Chemicals:** paraformaldehyde (MESH:C003043), EDTA (MESH:D004492), CO2 (MESH:D002245), paraffin (MESH:D010232), PBS (MESH:D007854), His (MESH:D006639), formalin (MESH:D005557), 4',6 - diamidino - 2 - phenylindole (MESH:C007293), Opal (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12856236/full.md

---
Source: https://tomesphere.com/paper/PMC12856236